Get the Stockscreener App
23.74
1.25%
-0.30
After Hours:
23.68
-0.06
-0.25%
Lenz Therapeutics Inc stock is traded at $23.74, with a volume of 250.18K.
It is down -1.25% in the last 24 hours and up +1.50% over the past month.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
See More
Previous Close:
$24.04
Open:
$24.06
24h Volume:
250.18K
Relative Volume:
1.58
Market Cap:
$652.77M
Revenue:
-
Net Income/Loss:
$-69.47M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-73.92M
1W Performance:
+10.21%
1M Performance:
+1.50%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$22.73
$25.41
1-Week Range:
$21.40
$25.41
52-Week Range:
$14.42
$25.77
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Name
Lenz Therapeutics Inc
Sector
Industry
Phone
858-925-7000
Address
445 MARINE VIEW AVE SUITE 320, DEL MAR
Lenz Therapeutics Inc Stock (LENZ) Latest News
LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences - The Manila Times
Achieve, INmune, Lenz gain on bullish initiations from Raymond James - MSN
Achieve, INmune, Lenz stocks win bullish view from RayJay - Seeking Alpha
Raymond James bullish on Lenz Therapeutics stock, highlights large presbyopia market - Investing.com
LENZ Therapeutics (NASDAQ:LENZ) Now Covered by Analysts at Raymond James - MarketBeat
Raymond James bullish on Lenz Therapeutics stock, highlights large presbyopia market - Investing.com India
Raymond James Initiates Coverage of LENZ Therapeutics (LENZ) with Outperform Recommendation - MSN
Neumora Therapeutics Inc. (NMRA) gets rating Initiated from Needham - Knox Daily
Understanding the Risks of Investing in LENZ Therapeutics Inc. (LENZ) - Knox Daily
Bank of New York Mellon Corp Has $746,000 Stock Holdings in Porch Group, Inc. (NASDAQ:PRCH) - Defense World
Bank of New York Mellon Corp Buys 2,771 Shares of BlackRock MuniYield Quality Fund, Inc. (NYSE:MQY) - Defense World
It is Poised to be a Bull Market for LENZ Therapeutics Inc. (LENZ) - SETE News
Humacyte Inc (HUMA) rating initates by H.C. Wainwright - Knox Daily
Bank of New York Mellon Corp Grows Stock Position in Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Bank of New York Mellon Corp Increases Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Insider Robert A. Lenz Sells 30,788 Shares of Stock - Defense World
NMRA (Neumora Therapeutics Inc.) may reap gains as insiders became active recently - Knox Daily
Victory Capital Management Inc. Has $6.38 Million Stock Holdings in MillerKnoll, Inc. (NASDAQ:MLKN) - Defense World
Arizona State Retirement System Increases Stock Position in ICU Medical, Inc. (NASDAQ:ICUI) - Defense World
Arizona State Retirement System Raises Holdings in Cavco Industries, Inc. (NASDAQ:CVCO) - Defense World
LENZ Therapeutics (NASDAQ:LENZ) Stock Price Up 7.8% - MarketBeat
Neumora Therapeutics Inc. [NMRA] Records 50-Day SMA of $11.52 - Knox Daily
LENZ Therapeutics Insiders Up US$178k On US$551.1k Investment - Yahoo Finance UK
LENZ Therapeutics Insiders Up US$178k On US$551.1k Investment - Yahoo Finance
LENZ Therapeutics Inc. (LENZ) may enjoy gains as insiders got busy in the recent days - Knox Daily
Monitoring Barrett Business Services Inc. (BBSI) after recent insider movements - Knox Daily
Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) PT at $35.00 - MarketBeat
Nexus Industrial REIT (TSE:NXR.UN) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Softcat plc (LON:SCT) Receives Average Rating of “Hold” from Analysts - Defense World
A company insider recently bought 3,188 shares of LENZ Therapeutics Inc. [LENZ]. Should You Buy? - Knox Daily
Presbyopia Market: Epidemiology, Therapies, and Key Companies - openPR
Short Interest in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Expands By 8.8% - MarketBeat
LENZ Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
LENZ Therapeutics Rings the Closing Bell - Nasdaq
Lenz Therapeutics: Upcoming PDUFA, Strong Data, Some Risks (NASDAQ:LENZ) - Seeking Alpha
LENZ Therapeutics to Participate in Upcoming Investor Conferences - ForexTV.com
LENZ Therapeutics to Participate in Upcoming Investor Conferences - The Bakersfield Californian
LENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024 - InvestorPlace
What happened in optometry this week: August 19August 23 - Optometry Times
83,103 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Bought by Wealth Enhancement Advisory Services LLC - MarketBeat
LENZ Therapeutics, Inc. (NASDAQ:LENZ) to Post Q3 2024 Earnings of ($0.59) Per Share, HC Wainwright Forecasts - MarketBeat
Zacks Research Analysts Boost Earnings Estimates for International Business Machines Co. (NYSE:IBM) - Defense World
HC Wainwright Analysts Boost Earnings Estimates for Omega Therapeutics, Inc. (NASDAQ:OMGA) - Defense World
Atb Cap Markets Equities Analysts Boost Earnings Estimates for Superior Plus Corp. (TSE:SPB) - Defense World
Naples Global Advisors LLC Takes $237,000 Position in General Electric (NYSE:GE) - Defense World
Essex Property Trust, Inc. (NYSE:ESS) Shares Sold by Swedbank AB - Defense World
Vanguard Group Inc. Purchases Shares of 206,952 LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
206,952 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Purchased by Vanguard Group Inc. - MarketBeat
FY2028 EPS Estimates for LENZ Therapeutics, Inc. Lowered by Analyst (NASDAQ:LENZ) - Defense World
Alarm.com Holdings, Inc. (NASDAQ:ALRM) Shares Bought by Cwm LLC - Defense World
LENZ Therapeutics (NASDAQ:LENZ) Stock Rating Reaffirmed by Piper Sandler - Defense World
Lenz Therapeutics Inc Stock (LENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):